Home Data Calendar Blog

BBIO

Tables

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Common Stock Value 0.160.150.150.150.150.150.150.120.120.120.12
Weighted Average Number Of Diluted Shares Outstanding 147.94146.68NANA146.66146.75NANANANANA
Weighted Average Number Of Shares Outstanding Basic 147.94146.68NANA146.66146.75NANANANANA
Weighted Average Number Of Share Outstanding Basic And Diluted NANA145.88NA146.66146.75138.63NA118.17NA117.07
Earnings Per Share Basic -0.93-0.07NANA-1.06-0.66NANANANANA
Earnings Per Share Diluted -0.93-0.07NANA-1.06-0.66NANANANANA
Earnings Per Share Basic And Diluted NANA-1.35-1.02-1.06-0.66-1.18-1.01-0.98-0.62-0.51

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Revenue From Contract With Customer Excluding Assessed Tax 0.3473.751.6912.892.3454.020.460.128.1313.8226.74
Revenues 0.3473.751.6912.892.3454.020.460.128.1313.8226.74
Costs And Expenses 129.45153.92175.37178.50151.84148.04167.97127.61128.07NANA
Research And Development Expense 92.51108.40107.65122.20104.31101.96122.5690.1792.0557.4855.28
Selling General And Administrative Expense 31.1936.4343.7154.7546.0845.9745.4137.4436.02NANA
Operating Income Loss -129.12-80.18-173.68-165.61-149.50-94.02-167.50-127.49-119.94-78.64-54.53
Interest Expense 19.8220.2820.3415.1311.0710.849.7410.9610.933.042.11
Interest Expense Debt 8.548.538.538.528.518.517.10NA8.21NANA
Interest Paid Net 22.146.6318.811.5317.431.908.912.049.161.761.75
Allocated Share Based Compensation Expense 18.6628.3024.2822.5116.1332.0334.9012.1517.7010.015.78
Profit Loss -140.19-2.56-201.33-152.28-161.02-102.07-171.08-135.03-130.17-84.15-60.66
Comprehensive Income Net Of Tax -137.26-9.90-196.65-147.33-155.95-96.25-163.33-120.25-116.26-56.05-60.51
Net Income Loss Available To Common Stockholders Basic -137.34-9.86-196.40-147.18-155.94-96.35-163.08-119.98-115.86-73.46-59.98

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Assets 728.74862.23813.151012.79781.521081.491093.31703.59787.69631.68640.53
Liabilities 1859.111877.251853.841878.371517.401537.111481.40595.70569.31155.70116.26
Liabilities And Stockholders Equity 728.74862.23813.151012.79781.521081.491093.31703.59787.69631.68640.53
Stockholders Equity -1138.42-1025.53-1041.00-870.41-743.40-464.29-395.2957.91163.76408.45459.76

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Assets Current 642.22771.28716.23888.86639.71909.87945.11642.82745.38568.62558.15
Cash And Cash Equivalents At Carrying Value 483.24470.10371.55393.77180.35378.42471.18356.08366.97363.77413.97
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 485.79472.65374.19NA183.08381.13473.77NANANANA
Marketable Securities Current 75.08218.47261.90393.74419.26459.24447.94251.01343.71182.22NA
Prepaid Expense And Other Assets Current 25.6632.7534.0232.4531.9326.6725.5335.7326.7022.6322.10
Equity Securities Fv Ni 33.6627.1437.7749.15NANANANANANANA
Available For Sale Securities Debt Securities 525.67475.76520.31626.84488.91775.59863.27517.45609.39521.10554.55

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Amortization Of Intangible Assets 0.600.600.901.300.70NANANANANANA
Property Plant And Equipment Net 15.6016.8717.1830.0727.7426.2722.8220.3216.185.622.98
Intangible Assets Net Excluding Goodwill 29.3129.9130.4844.9346.20NANANANANANA
Finite Lived Intangible Assets Net 29.3129.9130.4844.9346.20NANANANANANA
Other Assets Noncurrent 29.8731.3235.3333.0333.0549.8030.1823.9316.4826.292.60
Equity Securities Fv Ni 33.6627.1437.7749.15NANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Liabilities Current 119.19141.16103.46135.0795.82131.9194.7395.6575.7160.3839.86
Accounts Payable Current 10.168.7910.1111.8812.0422.3310.348.959.848.8510.27
Other Accrued Liabilities Current 23.8431.9824.7830.2814.6121.1818.2513.35NA3.023.22

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Long Term Debt Noncurrent NANA434.11430.75103.14102.6190.7692.4293.3991.7975.02
Minority Interest 10.4312.02-0.033.414.566.805.9348.3552.0665.2861.94
Other Liabilities Noncurrent 28.2328.6326.8322.0727.5813.2711.619.5213.473.531.39
Operating Lease Liability Noncurrent 13.0014.2815.4917.4318.6818.0213.8614.688.24NANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Stockholders Equity -1138.42-1025.53-1041.00-870.41-743.40-464.29-395.2957.91163.76408.45459.76
Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1127.98-1013.51-1041.02-867.00-738.84-457.49-389.37106.26215.81473.73521.70
Common Stock Value 0.160.150.150.150.150.150.150.120.120.120.12
Additional Paid In Capital Common Stock 917.33892.96867.60841.53821.22799.68767.121021.341006.94848.11826.06
Retained Earnings Accumulated Deficit -1780.56-1643.22-1633.36-1436.97-1289.79-1133.85-1037.51-888.75-768.77-440.03-366.57
Accumulated Other Comprehensive Income Loss Net Of Tax -0.35-0.43-0.38-0.130.020.04-0.060.190.460.25NA
Treasury Stock Value 275.00275.00275.00275.00275.00130.31125.0075.00NANANA
Minority Interest 10.4312.02-0.033.414.566.805.9348.3552.0665.2861.94
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 23.2323.9025.42NA16.9032.5119.84NA11.75NANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Net Cash Provided By Used In Operating Activities -135.16-30.45-160.63-133.90-121.56-91.71-150.76-96.26-131.68-76.20-50.00
Net Cash Provided By Used In Investing Activities 146.86149.70138.6221.8058.970.46-282.0583.02-45.05-16.90-197.34
Net Cash Provided By Used In Financing Activities 1.45-20.80-0.16325.38-135.46-1.39547.914.532.7842.90367.51

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Net Cash Provided By Used In Operating Activities -135.16-30.45-160.63-133.90-121.56-91.71-150.76-96.26-131.68-76.20-50.00
Profit Loss -140.19-2.56-201.33-152.28-161.02-102.07-171.08-135.03-130.17-84.15-60.66
Depreciation Depletion And Amortization 1.651.581.881.530.273.490.570.43-1.01NANA
Increase Decrease In Accounts Payable 1.36-1.28-1.811.47-11.6611.231.79-1.28-3.44-1.42-3.38
Share Based Compensation 17.3628.2924.1219.7716.0430.1133.5812.1517.7010.015.78

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Net Cash Provided By Used In Investing Activities 146.86149.70138.6221.8058.970.46-282.0583.02-45.05-16.90-197.34
Payments To Acquire Property Plant And Equipment 0.762.400.862.546.462.291.962.150.551.750.38

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Net Cash Provided By Used In Financing Activities 1.45-20.80-0.16325.38-135.46-1.39547.914.532.7842.90367.51

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Revenues 0.3473.751.6912.892.3454.020.460.128.1313.8226.74
Bristol Myers Squibb Company, Navire Pharma Inc, Research And Development Expense, License And Collaboration Agreement -0.103.20NANANANANANANANANA
Bristol Myers Squibb Company, Navire Pharma Inc, License And Collaboration Agreement -0.1073.40NANANANANANANANANA
Lian Bio, License, License Agreement 0.30NANA0.000.008.50NANANANANA
License NANA0.2310.841.5853.040.46-0.138.00NANA
License And Service 0.3473.75NANA1.5853.04NANANANANA
Product 0.000.001.462.050.760.99NANANANANA
Revenue From Contract With Customer Excluding Assessed Tax 0.3473.751.6912.892.3454.020.460.128.1313.8226.74
Bristol Myers Squibb Company, Navire Pharma Inc, Research And Development Expense, License And Collaboration Agreement -0.103.20NANANANANANANANANA
Bristol Myers Squibb Company, Navire Pharma Inc, License And Collaboration Agreement -0.1073.40NANANANANANANANANA
Lian Bio, License, License Agreement 0.30NANA0.000.008.50NANANANANA
License NANA0.2310.841.5853.040.46-0.138.00NANA
License And Service 0.3473.75NANA1.5853.04NANANANANA
Product 0.000.001.462.050.760.99NANANANANA

Plots across concepts


IncomeStatement
Comprehensive Income Net Of Tax
Balance Sheet
Stockholders Equity
Assets
Operating Lease Right Of Use Asset
Current Assets
Prepaid Expense And Other Assets Current
NonCurrent Assets
Operating Lease Right Of Use Asset
Liabilities
Operating Lease Liability
Current Liabilities
Operating Lease Liability Current
Noncurrent Liabilities
Minority Interest
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInInvestingActivities
Proceeds From Sale Of Productive Assets
NetCashProvidedByUsedInFinancingActivities
Repayments Of Long Term Debt
Shares
Treasury Stock Shares
OperatingLeaseLiability
Operating Lease Liability Current
NonoperatingIncomeExpense
Nonoperating Income Expense
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
FiniteLivedIntangibleAssets
Finite Lived Intangible Assets Accumulated Amortization

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:Revenues
us-gaap:ProductOrService
(None,)
Revenuesus-gaap: Product Or Service
us-gaap:InterestExpenseDebt
us-gaap:DebtInstrument
(None,)
Interest Expense Debtus-gaap: Debt Instrument
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:ConsolidatedEntities, us-gaap:IncomeStatementLocation
('bbio:BridgeBioServicesInc', None)
Allocated Share Based Compensation Expenseus-gaap: Consolidated Entities, us-gaap: Income Statement Location
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)
Allocated Share Based Compensation Expenseus-gaap: Income Statement Location
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:ConsolidatedEntities
(None,)
Allocated Share Based Compensation Expenseus-gaap: Consolidated Entities
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:AwardType, us-gaap:PlanName
(None, 'bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan')
Allocated Share Based Compensation Expenseus-gaap: Award Type, us-gaap: Plan Name
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByAssetClass, us-gaap:InvestmentType
(None, 'us-gaap:ShortTermInvestments')
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Asset Class, us-gaap: Investment Type
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents
(None,)
Stockholders Equity Including Portion Attributable To Noncontrolling Interestus-gaap: Statement Equity Components
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
us-gaap:StatementEquityComponents
(None,)
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Valueus-gaap: Statement Equity Components
us-gaap:Revenues
us-gaap:ProductOrService
(None,)
Revenuesus-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service